Correlation of elevated C1q binding activity and carcinoembryonic antigen levels with clinical features and prognosis in bronchogenic carcinoma.
The presence of immune complexes and carcinoembryonic antigen (CEA) was investigated in 50 patients with bronchogenic carcinoma at the time of and/or following diagnostic or definitive surgery. Immune complexes were measured by the C1q binding test and CEA by the Z gel method and elevations defined as values in excess of 2 S.D. above the normal mean, greater than or equal to 9.2% for C1q binding activity (C1q-BA) and greater than or equal to 5.0 ng/ml for CEA. The overall incidence of elevated values was 30.7% for C1q-BA and 34.2% for CEA. There was a greater incidence of elevated values of C1q-BA among patients with clinically evident disease. The differences with respect to CEA elevation were not significant due to the fact that 6 of 9 samples with elevated CEA values obtained from patients with no evident disease were in fact associated with the presence of clinically undetectable disease in these patients. Elevation of C1q-BA and CEA beyond the immediate postoperative period was predictive of a significantly shorter median survival time. The most significant differences in survival time were seen between patients with normal values for C1q-BA and CEA and those with elevations of one or both parameters, 6.0 vs. 19.5 months (p less than 0.001). Elevation of either parameter during the immediate pre- and postoperative period was not predictive of a poor survival. In terms of clinical application, it appears that CEA estimation had the best predictive value but that the addition of C1q-BA measurement may provide additional prognostic information, particularly in patients who do not have elevated CEA values.
D000230:Adenocarcinoma / Q000276:immunology; D000936:Antigen-Antibody Complex; D001500:BCG Vaccine / Q000494:pharmacology; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002283:Carcinoma, Bronchogenic / Q000276:immunology* / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D003172:Complement C1 / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy; D011379:Prognosis
D000936:Antigen-Antibody Complex; D001500:BCG Vaccine; D002272:Carcinoembryonic Antigen; D003172:Complement C1